McDonald 2017 finally receives PTAC recognition
Still unfunded, but finally acknowledged, McDonald 2017 criteria for diagnosing Multiple Sclerosis (MS) is one step closer to being used in NZ for accessing treatment. The February 2021 minutes of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC) were released this month, recommending a medium priority to funding the access criteria to include McDonald 2017 MS. “The Committee […]